The future of the pharmaceutical industry will involve increased use of master protocols, trial platforms and clinical-trial networks, said CDER director Janet Woodcock this week at a National Academies of Sciences, Engineering and Medicine workshop on real-world evidence in Washington, D.C.
Source: Drug Industry Daily